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ABSTRACT
Primary ciliary dyskinesia (PCD) is an inherited
autosomal-recessive disorder of motile cilia characterised
by chronic lung disease, rhinosinusitis, hearing
impairment and subfertility. Nasal symptoms and
respiratory distress usually start soon after birth, and by
adulthood bronchiectasis is invariable. Organ laterality
defects, usually situs inversus, occur in ∼50% of cases.
The estimated prevalence of PCD is up to ∼1 per
10 000 births, but it is more common in populations
where consanguinity is common. This review examines
who to refer for diagnostic testing. It describes the
limitations surrounding diagnosis using currently
available techniques and considers whether recent
advances to genotype patients with PCD will lead to
genetic testing and screening to aid diagnosis in the
near future. It discusses the challenges of monitoring
and treating respiratory and ENT disease in children
with PCD.
INTRODUCTION
Primary ciliary dyskinesia (PCD) is a genetic dis-
order that is almost invariably inherited as an
autosomal-recessive condition. It is characterised by
recurrent and chronic infections of the upper and
lower respiratory tracts, with symptoms starting
soon after birth caused by impaired mucociliary
clearance (MCC). Motile cilia are microscopic hair-
like organelles on the apical surface of epithelial
cells. In healthy individuals, cilia clear airway
mucus, bacteria and debris by coordinated beating.
PCD is caused by abnormality of ciliary beating,
which is often, but not always, associated with
abnormal ciliary structure (ﬁgures 1 and 2). In
addition to the lungs, motile cilia are found in the
middle ear, paranasal sinuses, female reproductive
tract and ependyma of the brain. Therefore, the
majority of patients with PCD have non-chest
symptoms; for example, in a cohort of 78 patients,
95% reported recurrent otitis media and 54% had
signiﬁcant sinus disease.1 Motile cilia on the embry-
onic node have an important role determining left-
right symmetry accounting for ≈50% of PCD
patients having situs inversus.2
EPIDEMIOLOGY
PCD has variable reported prevalence across
Europe reﬂecting true variability as well as differ-
ences in access to diagnostic facilities.3 Commonly
quoted ﬁgures for prevalence are between 1:4000
and 1:40 000, with the true prevalence probably
about 1:10 0003 4 and higher rates in certain
ethnic groups.5 6
Diagnosis is often delayed or missed completely.
One study reported that 70% of patients had seen
a physician >50 times before the diagnosis was
made.6 A European survey showed a median age of
diagnosis of 5.3 years, lower in children with situs
inversus (3.5 years vs 5.8 years).3
Most observational studies in PCD have been
cross-sectional, and knowledge of prognosis is
based on a handful of longitudinal studies with
relatively few patients. Although some patients
have a fairly benign course, lung function can
already be signiﬁcantly impaired in childhood1 7 8
and disease progression can be rapid. In a cohort of
adults with PCD, 98% had bronchiectasis, and
38% had severe lung disease with FEV1 < 40%
predicted.1 A recent study has reported signiﬁcantly
lower BMI in patients with PCD than those with
pancreatic insufﬁcient as well as pancreatic sufﬁ-
cient cystic ﬁbrosis (CF).7 These studies dispel any
suggestion that PCD is a mild disease.9
Provision of PCD care varies across Europe. A
survey of PCD management from 196 centres in 26
European countries showed that care was not cen-
tralised in most countries. There was a median of
only four patients (IQR 2–9) per centre and man-
agement was very variable.10 The authors con-
cluded that it was essential to standardise
management and decrease inequalities between
countries.
In England, the Department of Health recently
commissioned four national Paediatric PCD
Centres to complement the existing diagnostic
centres.11 12 The four centres, based in Leeds/
Bradford, Leicester, London and Southampton,
have been commissioned to provide an annual
review by a multidisciplinary team of ENT and
respiratory PCD specialists for children from
England and Scotland plus additional service as
outlined below (see ‘Management’ section).
DIAGNOSIS
A high level of suspicion is required to ensure early
diagnosis and start of appropriate management
before irreversible lung damage sets in. Diagnostic
investigations are complex, requiring expensive
infrastructure and an experienced team of clinicians
and scientists,12 thus tertiary respiratory centres
play an important role, gatekeeping referrals and
performing brushings for patients where travel to a
diagnostic service is difﬁcult.
European consensus guidelines13 reﬂect a diver-
sity of methods to support diagnosis, with no single
‘gold standard’ investigation.
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History
Paediatricians and neonatologists should have a low threshold to
refer patients with symptoms suggestive of PCD (box 1) to a
specialist diagnostic centre or to a respiratory centre for further
evaluation. Neonates typically present with respiratory distress
and rhinitis. Respiratory symptoms are present in 65–87%1 14
of neonates and range from mild transient tachypnoea to signiﬁ-
cant respiratory failure requiring prolonged respiratory support.
Unexplained respiratory distress in term neonates, particularly if
accompanied by atelectasis, should raise the suspicion of PCD.
Figure 1 Cartoon of a respiratory
cilium in transverse section as seen by
transmission electron microscopy
(TEM). Respiratory cilia have a ‘9+2’
arrangement with a central pair of
single microtubules running the length
of the ciliary axoneme surrounded by
nine peripheral microtubule doublets.
Nexin and radial spokes maintain the
organisation of the axonemal
structure. Attached to the peripheral
microtubules are inner and outer
dynein arms that generate the force for
ciliary beating. Abnormalities of the
dynein arms affect ciliary beating.
HYDIN projections on the central pair
of microtubules are not usually seen by
routine TEM (Cartoon image provided
by Robert L Scott).
Figure 2 Transmission EM of a respiratory cilia from (A) a healthy individual. Representative nasal epithelium cilia from patients with primary
ciliary dyskinesia (PCD) caused by (B) outer and inner dynein arm defects (C) transposition defect: some cilia demonstrate absence of a central
microtubule pair (‘9+0’); in other cilia a peripheral microtubule doublet has crossed to take the central position providing an apparent ‘8+2’
structure (D) microtubular disorganisation. EM images obtained using FEI Tecnai 12 transmission electron microscope (FEI UK Limited, Cambridge,
UK) at 80 kV). EM images provided by P Goggin (Primary Ciliary Dyskinesia Centre, University Hospitals Southampton NHS Foundation Trust,
Southampton, UK).
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Although rhinitis is difﬁcult to assess in neonates, in the
authors’ experience, many parents report that a blocked nose
was a problem from soon after delivery.
Infants typically have a persistent wet cough and recurrent
respiratory infections, which continue throughout childhood
and adulthood. Due to the underlying pathology, the cough is
almost invariably wet and is present on a daily basis unless sup-
pressed by the patient. In the authors’ experience, such suppres-
sion is common, as is under-recognition of the symptoms that
have been present since birth by parents. Bronchiectasis can
present in infancy and is almost invariable by adulthood,1 pre-
dominantly affecting the lower and middle lobes.
Persistent rhinitis occurs in most PCD patients,14 and symp-
toms of sinusitis often develop in childhood. Many patients
suffer from glue ear associated with conductive hearing difﬁ-
culty, which often ﬂuctuates although it can be persistent.
Situs anomalies occur in ≈50% of PCD patients, and these
may be associated with congenital cardiac disease.2 Patients with
situs anomalies should be referred for diagnostic testing if they
have any additional features suggestive of PCD, for example, ear
disease or wet cough. Respiratory symptoms in patients with
complex cardiac disease associated with heterotaxy might errone-
ously be attributed to their cardiac condition; a very low thresh-
old for referral for PCD diagnostic testing is important in this
patient group, particularly as a diagnosis of PCD impacts on peri-
operative management and prognosis.15 The incidence of situs
anomalies in the general population is approximately 1:10 000,
but there have been no studies to determine how many of these
people have PCD; a widely quoted estimate is 25%.
The structure of the sperm ﬂagella is similar to the ultrastruc-
ture of cilia, accounting for the common association of male
infertility with PCD while women with PCD can be subfertile
due to impaired ciliary function in the fallopian tubes.
Diagnostic tests
Historically, the saccharine test was advocated as a screening test
for PCD. Delayed perception of the taste from a small particle
of saccharin placed on the inferior turbinate may indicate a
problem with ciliary clearance, but results are unreliable and the
saccharine test is no longer recommended as a screening test for
PCD.13
Nasal nitric oxide (nNO) levels are almost universally low in
PCD patients,16 making this a good screening test that is advocated
across Europe13 and North America.17 18 Several commercially
available NO analysers are available that are capable of measuring
nNO levels, by sampling nasal gas. Using the ‘gold standard’ tech-
nique,19 a nasal olive probe with central lumen is placed into one
nostril and the other nostril is left patent, with a sampling tube
from the olive to a chemiluminescence analyser. The patient is
asked to hold their breath while performing a velum closure man-
oeuvre (eg, mouth exhalation against resistance). This breath-hold
with velum manoeuvre can be difﬁcult particularly for young chil-
dren, and there is mounting evidence that simpler measurements
such as breath-hold without velum closure or sampling during
tidal breathing can discriminate between PCD and non-PCD
patients.20–22 Standardisation of nNO analysis and reporting23 is
now needed, with particular need for reference cut-off values for
different analysers and respiratory manoeuvres. nNO should not
be used as an isolated diagnostic test because low levels are occa-
sionally reported in patients with CF, sinusitis, nasal polyposis or
other causes of nasal obstruction and acute infections. High or
normal nNO levels in a patient with PCD should lead to reassess-
ment of the diagnosis, although normal levels are occasionally
described in PCD.16
Assessment of ciliary ultrastructure by transmission electron
microscopy (TEM) was previously considered the ‘gold stand-
ard’ test for PCD, and remains an important investigation. At
least 100 cilia from healthy areas of epithelium obtained by
nasal or bronchial brush biopsy are analysed in transverse
section.24 Nasal ciliated epithelial cells can be obtained by
rubbing a cytology brush along the inferior turbinate in a pro-
cedure that is uncomfortable but lasts only a few seconds.
Tertiary respiratory centres can take the samples and transport
the cells in culture medium and ﬁxative to a diagnostic centre
for analysis.
Respiratory cilia consist of nine microtubule pairs surrounding
a central pair of singlet microtubules (ﬁgures 1 and 2); this gives
a cross-sectional 9+2 pattern. Microtubule-associated proteins
responsible for ciliary beating include inner and outer dynein
motor ‘arms’ that generate ATP-powered coordinated micro-
tubule sliding. Radial spoke and nexin–dynein regulatory com-
plexes work together with the central pair microtubules to
regulate the dynein activity to govern the force and waveform
stroke pattern of cilia. Ultrastructural defects causing PCD
include absence of the outer dynein arms from the outer doub-
lets, missing central pairs and disarrangement of the microtu-
bules (ﬁgure 2). However, 3–30% of patients with PCD are
reported25 26 to have uncertain or normal cilia ultrastructure,
thus TEM cannot rule out PCD.
Assessment of ciliary beat frequency (CBF) and ciliary beat
pattern (CBP), from a brush biopsy of epithelium, can exclude a
diagnosis of PCD if both are normal. Cilia are observed by high-
resolution, high-speed video microscopy with slow-motion-
replay.27 Abnormalities of CBP include static, slow, rotating and
hyper-frequent cilia with an incomplete beat, and these dysmo-
tile patterns are often linked with speciﬁc TEM defects.28
Abnormalities of CBF, CBP and TEM can occur secondary to
infection or inﬂammation of the epithelia; therefore, reanalysis
of the CBF, CBP and TEM following culture of the epithelial
cells at an air–liquid interface (ALI)29 with re-differentiation of
cilia is used to eliminate secondary defects.
Thus, a combination of techniques including nNO, CBF, CBP,
TEM and culture at ALI may all contribute to a diagnosis of PCD,
but despite expert evaluation, results can remain inconclusive and
repeated testing is often required. Investigations providing
Box 1 Who should be referred for diagnostic testing?
1. Situs inversus plus respiratory or nasal symptoms
2. Neonatal respiratory distress of unknown cause
3. Sibling with primary ciliary dyskinesia (PCD), particularly if
symptomatic
4. Daily lifelong wet cough (note: maybe suppressed by child
and under-recognised by parents)
5. If considering testing for cystic ﬁbrosis, also consider testing
for PCD particularly if rhinitis, sinusitis or glue ear are present
6. Unexplained bronchiectasis
7. Serous otitis media in association with lower and upper
airway symptoms
8. Cardiac disease associated with heterotaxy if there is
suspicion of respiratory, nasal or ear problems
NB: A lower threshold for referral should be considered if the
patient is from a consanguineous background or is of an ethnic
origin known to have increased prevalence of PCD.
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additional information include radioaerosol MCC30 31 as an in
vivo measure of ciliary function and immunoﬂuorescence-labelled
antibodies32 to demonstrate absence of cilia axonemal and cyto-
plasmic preassembly of proteins. EM tomography may be of assist-
ance in identifying the ultrastructural defect where standard
tomography has not resolved the abnormality.33 However, MCC,
IF and EM tomography are only available in a few centres around
the world and are not included in the diagnostic service commis-
sioned in the UK.12 Recent advances to identify the genes asso-
ciated with PCD provide hope for genetic testing as an addition to
diagnostic testing. It is currently estimated that genetic testing can
detect 65% of patients with PCD,17 and genetic testing is increas-
ingly used as an adjunct test, particularly for difﬁcult-to-diagnose
cases with undetermined TEM or CBF studies and/or unusual clin-
ical characteristics (see ‘Genetics’ section).
MANAGEMENT
There have been no long-term randomised trials of therapy in
PCD, and there is a lack of evidence-based medicine in the man-
agement of this condition. As a result, many aspects of patient
care are empirically based on other chronic suppurative lung
disease, particularly CF.4 Best practice guidelines from specialist
centres managing large cohorts of patients have recently been
reviewed and collated to produce a European consensus;13
however, wide variations in approach to management exist.10
Despite many aspects of the care of the two diseases overlap-
ping, PCD should not be managed alongside CF. The multisys-
tem aspects of PCD differ from and require different
subspecialist input,9 and these needs may be ignored in the CF
setting. Nonetheless, a similar mind set of regular review in a
specialist centre, with targeted multisystem care, and an aggres-
sive approach to airway clearance and management of infec-
tions, should provide the cornerstone of therapy. The UK
model11 includes comprehensive evaluation by the MDT PCD
service at least once a year culminating in a personalised man-
agement plan. Depending on clinical and geographical factors,
the patient may have additional appointments throughout the
year by the PCD service or care may be shared with the patient’s
local specialist respiratory team. Appointments are scheduled to
provide three monthly assessments. A telephone advice line is
available to patients, their families and to professionals involved
in the patient’s care.
Respiratory management
Following diagnosis, the goals of respiratory management are the
initial improvement of any lung function deﬁcit and subsequent
limiting of disease progression. Treatment of lung disease is based
upon airway clearance therapy and aggressive antibiotic.
Age-appropriate daily ACT should be prescribed for every
patient and regularly reviewed. No individual technique has
been shown to be superior and a patient’s physiotherapy plan
should be individualised, with adjuncts incorporated if
appropriate.
ACT can be augmented with bronchodilators, exercise, muco-
lytics or mechanical cough assist, although there is paucity of
evidence for their use. Regular salbutamol inhalation pre-
physiotherapy is of unproven beneﬁt. Physical exercise
encourages secretion clearance as well as providing obvious
general health beneﬁts. Nebulised mucolytics remain unproven
as a treatment and can be expensive and time-consuming. There
are anecdotal reports that rhDNase is beneﬁcial in some
patients, but a study of adults with non-CF bronchiectasis
showed it to be ineffective and potentially detrimental.34 35
Oral N-acetylcysteine has been shown to have no beneﬁt in
patients with PCD.36 Based on evidence from bronchiectasis of
other aetiologies, hypertonic saline may be helpful.
Respiratory tract infections should be treated promptly and
aggressively. A prolonged course of high-dose oral antibiotics
can be prescribed in the settings of worsening respiratory symp-
toms, a deterioration in lung function or a positive culture.
Culture-independent analysis of PCD respiratory samples has
shown the bacteria present in PCD patient’s airways to be plen-
tiful and varied.37 The most commonly cultured pathogens are
Haemophilus inﬂuenzae, Staphylococcus aureus and
Streptococcus pneumonia. Pseudomonas aeruginosa and non-
tuberculous mycobacteria have also been reported, although
predominantly in adults.1 37 Intravenous antibiotics can be used
if there is no response to oral antibiotics. Patients with more
severe lung disease may require three monthly intravenous anti-
biotics to limit disease progression. Isolates of P aeruginosa are
treated with eradication protocols based on those used in CF,
and chronic infection is often treated with long-term nebulised
suppressive antibiotics. There is no evidence for or against the
use of antibiotic prophylaxis; however, in children requiring fre-
quent courses of antibiotics, they can be considered.
Children with coexisting asthma can be treated with β2 ago-
nists and inhaled corticosteroids in line with asthma guidelines,
but there is no evidence for anti-inﬂammatory treatment in
other settings.
Tobacco smoke exposure is likely to be harmful, and effective
support for smoking cessation should be offered to families.
Childhood immunisations should be administered along with
pneumococcal vaccination and annual inﬂuenza vaccination.
Finally, surgical intervention for lung disease in PCD is gener-
ally not recommended; however, in selected cases of severe, loca-
lised bronchiectasis, lobectomy can be considered. Bilateral lung
transplantation is an option for end-stage respiratory failure.
Monitoring
Monitoring the progressive lung disease in PCD is difﬁcult on
many fronts. Clinically, patients appear well, or report feeling ﬁne,
while objective tests might suggest otherwise. Despite retained
secretions and a history of chronic productive cough in most
patients, clinical examination may reveal few signs. For this
reason, patients with PCD should be regularly followed up by
experienced specialists who have access to an array of monitoring
tools to assess their airway disease. In the UK model, English and
Scottish patients have a comprehensive assessment as part of their
annual review by the PCD multidisciplinary team. Monitoring
throughout the year is conducted wherever the patient has their
shared care, but access to specialist monitoring by the PCD centre
is available between annual reviews if required.
Spirometry remains the ﬁrst line in monitoring lung function,
although it has recently been shown to be an insensitive marker
of deterioration of respiratory health in PCD. Progression of
lung disease, evident using high-resolution CT (HRCT), has
occurred while spirometric values have remained stable in some
patients.38 Although HRCT remains a useful staging test, it is an
impractical screening tool and efforts are underway seeking to
establish an affordable, readily accessible and reproducible test
to assist in the monitoring of PCD lung disease.
Multiple breath washout technique, or lung clearance index
(LCI), is likely to have potential as such a tool in specialist
centres. It appears more sensitive than spirometry and correlates
well with HRCT in CF. It is possible to test LCI in younger chil-
dren compared with spirometry, and in established laboratories
it can be done at each clinic visit if required. However, unlike in
CF, a recent study comparing LCI and HRCT scores in a cohort
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with PCD showed no correlation between these measurable
parameters,39 leading to speculation that the dissimilarities
between large and small airways disease in CF and PCD may be
one explanation to the different outcomes seen in these two
important causes of chronic suppurative lung disease.
ENT
Poor MCC of the upper respiratory tract leads to mucus
pooling within the middle ear cleft, nose and paranasal sinuses.
This results in a high incidence of otitis media with effusion
(46–86% of patients), hearing loss (25–36%) and nasal dis-
charge or blockage (76–88%).6 14 24 Where one would nor-
mally expect resolution of glue ear and nasal discharge in an
otherwise healthy child by 8 years, symptoms in PCD children
persist longer and not infrequently into adulthood.
The main ENT concern is persistent hearing loss that is linked
to otitis media with effusion. The role of ventilation tubes (VT)
is controversial. Most reports advise avoiding VTs as they simply
divert the mucus ﬂow through the ear drum causing longstand-
ing mucopurulent discharge.13 14 40 41 Hearing loss therefore
tends to be managed conservatively with hearing aids, educa-
tional support for hearing issues and, where appropriate, speech
therapy. Several reports challenge this, claiming good hearing
restoration following VT insertion with episodic discharge
causing no greater burden than in non-PCD patients.42–44
Should tympanic membrane perforations develop (particularly
after repeated VT insertion), tympanoplasty is generally success-
ful, but the glue ear often reoccurs.
Nasal symptoms usually manifest as persistent nasal discharge
and blockage. Nasal polyposis in childhood is rare. Nasal dis-
charge is best managed by irrigation. Prophylactic antibiotics
help minimise infective rhinosinusitis. Rarely is sinus surgery
necessary or found to be effective in reducing nasal discharge.
The sphenoid and frontal sinuses can be hypoplastic or even
aplastic.45 There is no proven role for the use of intranasal ster-
oids or antihistamines, but they are useful in treating any add-
itional allergic rhinosinusitis.
The role of adenotonsillectomy in removing any reservoir of
infection is yet unproven. Obstructive sleep apnoea and sleep-
disordered breathing are greater in PCD than in the general
population, but neither have been found to be directly linked to
increased adenotonsillar hypertrophy.
GENETICS
Rapid advances have increased understanding of the genetic basis
of PCD in recent years. Consistent with its clinical variability,
PCD is remarkably genetically heterogeneous, and mutations in
an expanding number of genes (nearly 30) are disease-causing.
The speciﬁc gene mutations correlate well to their cilia structural
defects, beat frequency and pattern (table 1). However, few spe-
ciﬁc genetic defects have yet been linked to any speciﬁc clinical
variability in patients, except for one speciﬁc mutation in the
CCDC114 gene carried by a population of patients who demon-
strate normal levels of fertility. In addition, outer dynein arm
gene defects may cause more laterality disturbances,2 while
central pair gene defects do not disturb laterality.33
Dynein arm defects (outer and/or inner) are the most common
ultrastructural defect, with microtubule, central pair and other
defects accounting for fewer cases.26 DNAH5 mutations cause
∼50% and DNAI1 mutations cause ∼10% of outer dynein arm
defects, while SPAG1 mutations cause ∼10% of inner and outer
dynein arm defects.46–48 Together, CCDC40 and CCDC39 muta-
tions account for ∼70% of PCD with microtubular disorganisa-
tion and inner dynein arm loss.49 Mutations in other genes are
rarer causes of PCD, and a large proportion of disease is not yet
genetically deﬁned.17 More difﬁcult-to-diagnose cases, for
example, those that do not have visible axonemal defects, are
now also being diagnosed genetically17 33 50 (table 1).
New next-generation sequencing (NGS) approaches are
proving efﬁcient for diagnosis and also identiﬁcation of new
PCD genes since they allow parallel sequencing of multiple can-
didate genes or of the entire exome.51 Technical developments
will continue to improve affordability, coverage and sequencing
quality of NGS approaches. Although NGS is not yet in routine
use for PCD diagnosis, it already presents a cost-efﬁcient and
effective gene diagnostic approach. A diagnostic gene panel
service has just been initiated within the North Thames
Regional Genetics service provided at Great Ormond Street
Hospital. This quick and comprehensive DNA-based diagnosis
can help facilitate the earlier diagnosis and interventions desired
to help patients with PCD, also providing diagnosis of PCD in
cases that proved very difﬁcult without molecular testing.33
Improved genetic diagnosis and determination of genetically
stratiﬁed patient populations will be the ﬁrst step required to
evaluate future gene-based therapy strategies in PCD, for
example, gene replacement therapy, aminoglycoside-induced
read-through therapy and pharmacogenetic approaches of the
type proving successful in CF.
SUMMARY
PCD is a genetically inherited disease with multisystem involve-
ment, with mutations in 27 genes identiﬁed to date. There has
Table 1 Genes in which mutations cause primary ciliary dyskinesia, with corresponding cilia structural defects
Gene Function of encoded protein Cilia ultrastructure in patients
DNAH5, DNAI1, DNAI2, DNAL1, NME8 Outer dynein arm subunit ODA
CCDC114, ARMC4 Outer dynein arm targeting/docking complex subunit ODA
DNAAF1, DNAAF2,DNAAF3,HEATR2, LRRC6, ZMYND10, DYX1C1, SPAG1 Cytoplasmic dynein assembly factor IDA+ODA
CCDC103, C21ORF59 Cytoplasm/cilia dynein assembly factor IDA+ODA
RSPH1, RSPH4A, RSPH9 Radial spoke head subunit CP
CCDC39, CCDC40 Nexin link (dynein regulatory complex) factor IDA+MT disarrangement
CCDC164, CCDC65 Nexin link (dynein regulatory complex) subunit Normal (nexin links absent)
HYDIN Central microtubule pair subunit Normal (CP subunit C2b absent)
DNAH11 Outer dynein arm subunit Normal
OFD1, RPGR Non-motile cilia-related functions Mixed
CP, central microtubule pair; IDA, inner dynein arm; MT, microtubule; ODA, outer dynein arm.
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been considerable international collaboration in recent years to
improve our knowledge of the syndrome and to improve the
evidence base for diagnosis and management. Currently, diagno-
sis remains uncertain in many cases, and management is largely
based on evidence from CF. To improve management of PCD, a
European funded FP7 collaboration is focusing on improving
diagnosis and treatment (http://www.bestcilia.eu/).
Paediatricians, neonatologists and ENT surgeons should main-
tain their awareness of PCD and make early referrals for diagno-
sis before the child has sustained irreversible lung damage. It is
anticipated that multicentre collaborations will improve the evi-
dence base for treatment.
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